Patents by Inventor David S. Yoon

David S. Yoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11970511
    Abstract: The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: April 30, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Li Xu, David S. Yoon, Alicia Regueiro-Ren, Prasada Rao Jalagam, Manoranjan Panda, Satheesh Kesavan Nair
  • Publication number: 20240067638
    Abstract: The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1, 5-a]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).
    Type: Application
    Filed: August 18, 2021
    Publication date: February 29, 2024
    Inventors: David S. Yoon, Alicia Regueiro-Ren, Andrew P. Degnan, Gang WU
  • Publication number: 20230295122
    Abstract: The present invention relates to 1H-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).
    Type: Application
    Filed: August 18, 2021
    Publication date: September 21, 2023
    Inventors: David S. Yoon, Alicia Regueiro-Ren, Michael Mandler, Shoshana L. Posy, Chunjian Liu
  • Publication number: 20220185800
    Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: March 25, 2020
    Publication date: June 16, 2022
    Inventors: Chunjian Liu, David S. Yoon, Wei Wang, Jianxin Feng, Bruce A. Ellsworth, Alicia Regueiro-Ren
  • Publication number: 20220009913
    Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: December 4, 2019
    Publication date: January 13, 2022
    Inventors: Jacob Swidorski, Brett R. Beno, David S. Yoon, Alicia Regueiro-Ren
  • Publication number: 20210323991
    Abstract: The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.
    Type: Application
    Filed: June 13, 2019
    Publication date: October 21, 2021
    Inventors: Richard A. Hartz, Li Xu, David S. Yoon, Alicia Regueiro-Ren, Prasada Rao Jalagam, Manoranjan Panda, Satheesh Kesavan Nair
  • Patent number: 10730863
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: August 4, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: David S. Yoon, Rushith Kumar Anumula, Srinivas Cheruku, Yanting Huang, Elizabeth Anne Jurica, Wei Meng, Susheel Jethanand Nara, Rishikesh Narayan, Ramesh Kumar Sistla, Ximao Wu, Guohua Zhao
  • Patent number: 10336684
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: July 2, 2019
    Assignee: Bristol=Myers Squibb Company
    Inventors: Peter T. W. Cheng, David S. Yoon
  • Publication number: 20190127358
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: October 31, 2018
    Publication date: May 2, 2019
    Inventors: David S. Yoon, Rushith Kumar Anumula, Srinivas Cheruku, Yanting Huang, Elizabeth Anne Jurica, Wei Meng, Susheel Jethanand Nara, Rishikesh Narayan, Ramesh Kumar Sistla, Ximao Wu, Guohua Zhao
  • Publication number: 20180319737
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
    Type: Application
    Filed: July 12, 2018
    Publication date: November 8, 2018
    Inventors: PETER T. W. CHENG, David S. Yoon
  • Publication number: 20170327457
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
    Type: Application
    Filed: September 8, 2015
    Publication date: November 16, 2017
    Inventors: Peter T.W. Cheng, David S. Yoon
  • Publication number: 20140128365
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: enantiomers, diastereomers, solvates, salts, tautomers or prodrugs thereof wherein, A, W, X, Y and R1 are defined herein.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 8, 2014
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Robl, Shung C. Wu, David S. Yoon
  • Patent number: 8318941
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure formula (I) enantiomers, diastereomers, solvates, salts, tautomers or prodrugs thereof wherein, A, W, X, Y and R1 are defined herein.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: November 27, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Robl, Shung C. Wu, David S. Yoon
  • Publication number: 20100009960
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure formula (I) enantiomers, diastereomers, solvates, salts, tautomers or prodrugs thereof wherein, A, W, X, Y and R1 are defined herein.
    Type: Application
    Filed: July 2, 2007
    Publication date: January 14, 2010
    Inventors: Jeffrey A. Robl, Shung C. Wu, David S. Yoon
  • Patent number: 6731627
    Abstract: A loop carrier system includes a home local area network having plural telephone modules and a hub coupled to in-home telephone wiring. The telephone modules and the hub communicate voice signals over the in-home wiring in a dedicated frequency band above baseband POTS. The hub converts between voice signals and voice packets and is connected to a network access device for transferring the voice packets from the home local area network to a telecommunications network which routes the voice packets to a gateway. The gateway converts between the voice packets and a circuit format compatible with a local digital voice switch.
    Type: Grant
    Filed: November 17, 1999
    Date of Patent: May 4, 2004
    Assignee: Cisco Technology, Inc.
    Inventors: Dev V. Gupta, Subra Dravida, Vikram Saksena, Paiman Nodoushani, Denis Claveloux, Sriram Narayan, Kyung-Yeop Hong, Anthony Monteiro, Wei Ye, David S. Yoon